Trial Profile
An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Pegcetacoplan (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
- Acronyms PLAUDIT
- Sponsors Apellis Pharmaceuticals
- 28 Mar 2023 Status changed from active, no longer recruiting to completed.
- 20 Nov 2020 Planned End Date changed from 1 Dec 2020 to 1 Jul 2022.
- 06 Feb 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.